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Introduction:  
VERDICT (Vascular, Extracellular, and Restricted Diffusion for Cytometry in 
Tumours) is a microstructural imaging technique that combines a detailed 
diffusion MRI acquisition with a mathematical model to map and measure 
microstructural tissue parameters. The technique has shown significant promise 
in the preclinical setting (1) and in a pilot study in prostate cancer (2), but to 
develop the technique for translational and clinical research, it must 
demonstrate technical validity. 
 
This study seeks to evaluate the short-term repeatability of VERDICT MRI in 
normal and cancerous prostate tissue. 
 
Materials and methods: 
5 men awaiting biopsy for suspected prostate cancer were identified and 
recalled for VERDICT MRI, with a median of 120 days (range 43- 151) from their 
original multiparametric prostate MRI.  
 
VERDICT DW-MRI was performed using a 3T scanner (Achieva, Philips 
Healthcare, Netherlands) using a series of pulse-gradient spin-echo sequences 
with various diffusion gradient strengths and timings (3). The series of scans was 
repeated following a 2-minute interval. The imaging parameters are shown in 
table 1. 
 
Diffusion model  
VERDICT is a three-compartment model that characterises diffusion in the 
vascular, extracellular-extravascular space (EES) and intracellular (IC) 
compartments in tumours. The prostate model has five parameters: fEES (EES 
volume fraction), fIC (IC volume fraction), cell radius R diffusivity D and pseudo-
diffusion P. A vascular volume fraction can be determined from fVASC=1- fIC- fEES. 
Cellularity maps are calculated by dividing fIC by the cube of the cell radius (cell 
volume) estimate. 
 
Image analysis 
MR datasets were analysed with Osirix Version 7.0 (Bernex, Switzerland). A 
board certified Radiologist (EJ) manually contoured a region of interest (ROI) on 
each prostate lesion, using the slice at the epicentre of the tumour. ROIs were 
drawn on the b=2000s/mm^2 image, using the previous mpMRI for further 
guidance. An ROI of equal size was then drawn in a normal region of the prostate, 
in the same zone, on the same slice. ROIs were copied onto the subsequent 
acquisition and manually refined accordingly. 
 
We fitted the VERDICT model to the data using a similar iterative optimization 
procedure to Panagiotaki et al. (1,2) that accounts for local minima and Rician 
noise. Fitting consisted in two steps, first the model was fitted to data averaged 
over all voxels of the prostate (tumor and benign regions) and then the fitting 
was performed in each voxel. Fitting was performed using the open source 
Camino toolkit (http://cmic.cs.ucl.ac.uk/camino/) (4). Apparent diffusion 
coefficient (ADC) was also fitted for comparison. 
 
An example of a multi-parametric (mp)MRI and the subsequent generated 
VERDICT maps are provided in figure 1. 
 
Statistical analysis 
Median ROI values were used for all parameters, as data was not normally 
distributed. Bland Altman plots were constructed and intraclass correlation 
coefficients (ICCs) (3,1) single measures, with absolute agreement calculated. 
 
Results: 
5 patients had a median age of 67.4 (range 58.0 – 74.6), a median prostate 
specific antigen (PSA) of 8.5 (range 3.3 – 18.0). Subsequent biopsy performed 
within a week of the scan confirmed prostate cancer in the peripheral zone (n=4) 
and transition zone (n=1), with Gleason scores of 3+3(n =1) and 3+4 (n=4). 
 
Bland-Altman plots were constructed; please see in figure 2 for interpretation. 
Intraclass correlation coefficients (ICCs) are provided in table 2. In accordance 
with Landis and Koch (5), the following ICC interpretation scale was used: poor 
to fair (below 0.4), moderate (0.41–0.60), excellent (0.61–0.80), and almost 
perfect (0.81–1). 
 
Discussion: 
To be clinically useful, any quantitative imaging technique must demonstrate 
accurate estimates of the measured biological parameter (accuracy) and be 
repeatable (precision) (6).  
 
Broadly, more complex biophysical models such as VERDICT provide a better fit 
to data than simpler models with fewer parameters, such as ADC, and our 
previous work has shown this to be the case (1,2). However, more complex 
models also tend to ‘overfit’ data, and become sensitive to noise, resulting in 
poor repeatability. 
 
In this study, we were able to compare the repeatability of parametric maps 
generated from VERDICT MRI to those of ADC. As expected, ADC demonstrated 
almost perfect agreement.  
 
Cellularity was the most reliable parameter with almost perfect agreement in 
both normal and cancerous prostate tissue. fIC and fEES were the next best 
performing, demonstrating almost perfect agreement in the normal prostate and 
excellent agreement in cancerous tissue. 
 
 
However, cell radius and fvasc demonstrated poor to moderate repeatability, 
with the latter likely due to relatively low contribution to MR signal. 
 
Conclusion 
Cellularity, fEES and fIC are repeatable VERDICT parameters. Further work is 
required to establish the medium and long-term repeatability of VERDICT, and 
for biological validation to determine what constitutes a clinically useful 
measurement. 
 
 
References: 
 
1.  Panagiotaki E, Walker-Samuel S, Siow B, et al. Noninvasive quantification 
of solid tumor microstructure using VERDICT MRI. Cancer Res. 2014 Apr 
1;74(7):1902-12 
 
2.  Panagiotaki E, Chan RW, Dikaios N, et al. Microstructural Characterization 
of Normal and Malignant Human Prostate Tissue With Vascular , 
Extracellular , and Restricted Diffusion for Cytometry in Tumours 
Investigative Radiology, 50 (4), 218-227.  
 
3.       Panagiotaki E, Ianus A, Johnston E et. al, Optimised VERDICT MRI protocol 
for prostate cancer characterisation. 24th Scientific Meeting of the 
International  Society for Magnetic Resonance in Medicine, Toronto, 
Canada 2015. 
 
4.       P. A. Cook, Y. Bai, S. Nedjati-Gilani, K. et. al, Camino: Open-Source Diffusion-
MRI Reconstruction and Processing, 14th Scientific Meeting of the 
International Society for Magnetic Resonance in Medicine, Seattle, WA, USA, 
p. 2759, May 2006. 
 
5.       Landis JR, Koch GG. The measurement of observer agreement for 
categorical data. Biometrics 1977;33:159-174. 
 
6. Tofts P. QA: quality assurance, accuracy, precision and phantoms. 2003; 
Available from: http://discovery.ucl.ac.uk/188427/. Accessed 8th 
November 2015. 
 
 
 
 
 
Acknowledgements: 
 
This work is funded by a grant from Prostate Cancer UK. BRC grant XXXX 
supports EJ and SP’s work on this topic. EPSRC grants G007748 and H046410 
support DA, EBC, and EP’s work on this topic.  
 
 
Figures and tables 
 
b value 
s/mm2 ∆/ δ ms TE ms 
|G| 
T/m 
3000 24.7/43.8 90 0.0439 
2000 13.2/32.3 67 0.0758 
1500 24.7/43.4 90 0.0311 
500 12.2/31.3 65 0.0415 
90 12.2/23.8 50 0.0506 
 
Table 1: Diffusion MRI protocol details for VERDICT analysis. 
 
 
 
 
  
Figure 1:  
Top - multiparametric prostate MRI showing a tumour in the right peripheral 
zone, between 7 and 10 o’clock. L >R: The tumour is low signal on T2, of low ADC 
value and high signal on B2000 and early DCE. 
Bottom images: Subsequent multiparametric VERDICT maps (acquisitions 1 and 
2) demonstrating similar qualitative repeatability. 
 
 
 
 
 
Figure 2: Bland-Altman plots, which show similar repeatability for tumour (right 
column) and non-tumour (left column) regions. ADC, fIC, fEES and cellularity 
maps demonstrate acceptable levels of agreement whereby the intersubject 
variation is greater than intrasubject (test-retest) variation. Units are: ADC 
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radius x10-6 cm 
 
Parameter Normal Tumour 
ADC 0.98 (0.84, 0.99) 0.90 (0.46, 0.99) 
fIC 0.97 (0.79, 0.99) 0.77 (-0.02, 0.97) 
fEES 0.87 (-0.12, 0.94) 0.76 (-0.30, 0.97) 
fvasc 0.52 (-0.23, 0.93) -0.09 (-0.70, 0.80) 
Radius -0.22 (-0.81, 0.80) -0.07 (-1.27, 0.84) 
Cellularity 0.95 (0.63, 0.99) 0.90 (0.42, 0.99) 
Table 2 ICCs (3,1) of VERDICT parameters. 95% CI (lower, upper) are provided 
 
 
 
